Answers are grounded in this paper and cite their sources.
Monoacylglycerol lipase (MAGL) is a promising therapeutic target for neuroinflammatory conditions. We have previously reported on MAGLi 432, a reversible MAGL inhibitor with activity in mouse models of neuroinflammation. In this full account, we report on the structure-guided optimization of a bicyclopiperazine (Bcpz) DEL hit into potent, selective and brain-penetrant reversible MAGL inhibitor 1.5 (MAGLi 432), guided by the “Five-Star Matrix” translational framework. Compound 1.5 combines excellent MAGL potency (IC50 = 3.2 nM) and selectivity over other serine hydrolases with favorable pharmacokinetic properties, including a 5.7 h half-life after oral administration in male Wistar rats, and CNS drug-like potential. Furthermore, as previously reported, the compound demonstrated robust brain penetration and efficacy in preclinical mouse models of neuroinflammation correlating with inhibition of MAGL activity in mouse and human brain homogenate. This work highlights the power of combining DEL screening and SBDD with the Five-Star Matrix to deliver drug-like candidates for neuroinflammatory disorders.
No takes yet. Share an insight, caveat, or question.
Brennecke et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: